Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 28, 2023 06:00 ET
|
Turnstone Biologics Corp.
Turnstone Biologics to present preclinical data for its Selected TILs at SITC's 38th Annual Meeting.
Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update
September 01, 2023 17:57 ET
|
Turnstone Biologics Corp.
Successfully closed upsized IPO, raising $88 million in gross proceeds to continue advancing pipeline of Selected TIL Therapy programsCash position expected to fund operations into second quarter of...
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering
July 21, 2023 02:15 ET
|
Turnstone Biologics Corp.
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure...